Proximagen, Upsher-Smith deal

Specialty pharma Upsher-Smith will acquire the 84% of Proximagen it does not already own for 320p per share in cash. The price, which values Proximagen at about £223 million

Read the full 294 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE